207 related articles for article (PubMed ID: 31810768)
1. Cryopreservation timing is a critical process parameter in a thymic regulatory T-cell therapy manufacturing protocol.
MacDonald KN; Ivison S; Hippen KL; Hoeppli RE; Hall M; Zheng G; Dijke IE; Aklabi MA; Freed DH; Rebeyka I; Gandhi S; West LJ; Piret JM; Blazar BR; Levings MK
Cytotherapy; 2019 Dec; 21(12):1216-1233. PubMed ID: 31810768
[TBL] [Abstract][Full Text] [Related]
2. Challenges in cryopreservation of regulatory T cells (Tregs) for clinical therapeutic applications.
Golab K; Leveson-Gower D; Wang XJ; Grzanka J; Marek-Trzonkowska N; Krzystyniak A; Millis JM; Trzonkowski P; Witkowski P
Int Immunopharmacol; 2013 Jul; 16(3):371-5. PubMed ID: 23428908
[TBL] [Abstract][Full Text] [Related]
3. Discarded Human Thymus Is a Novel Source of Stable and Long-Lived Therapeutic Regulatory T Cells.
Dijke IE; Hoeppli RE; Ellis T; Pearcey J; Huang Q; McMurchy AN; Boer K; Peeters AM; Aubert G; Larsen I; Ross DB; Rebeyka I; Campbell A; Baan CC; Levings MK; West LJ
Am J Transplant; 2016 Jan; 16(1):58-71. PubMed ID: 26414799
[TBL] [Abstract][Full Text] [Related]
4. Generation, cryopreservation, function and in vivo persistence of ex vivo expanded cynomolgus monkey regulatory T cells.
Guo H; Zhang H; Lu L; Ezzelarab MB; Thomson AW
Cell Immunol; 2015 May; 295(1):19-28. PubMed ID: 25732601
[TBL] [Abstract][Full Text] [Related]
5. Regulatory T cells from patients with end-stage organ disease can be isolated, expanded and cryopreserved according good manufacturing practice improving their function.
Ulbar F; Montemurro T; Jofra T; Capri M; Comai G; Bertuzzo V; Lavazza C; Mandelli A; Viganò M; Budelli S; Bacalini MG; Pirazzini C; Garagnani P; Giudice V; Sollazzo D; Curti A; Arpinati M; La Manna G; Cescon M; Pinna AD; Franceschi C; Battaglia M; Giordano R; Catani L; Lemoli RM
J Transl Med; 2019 Aug; 17(1):250. PubMed ID: 31383037
[TBL] [Abstract][Full Text] [Related]
6. Isolation and expansion of thymus-derived regulatory T cells for use in pediatric heart transplant patients.
Romano M; Sen M; Scottà C; Alhabbab RY; Rico-Armada A; Lechler RI; Burch M; Lombardi G
Eur J Immunol; 2021 Aug; 51(8):2086-2092. PubMed ID: 33949684
[TBL] [Abstract][Full Text] [Related]
7. An innovative method to generate a Good Manufacturing Practice-ready regulatory T-cell product from non-mobilized leukapheresis donors.
Zhang W; Smythe J; Frith E; Belfield H; Clarke S; Watt SM; Danby R; Benjamin S; Peniket A; Roberts DJ
Cytotherapy; 2015 Sep; 17(9):1268-79. PubMed ID: 26276008
[TBL] [Abstract][Full Text] [Related]
8. Consequences of adjusting cell density and feed frequency on serum-free expansion of thymic regulatory T cells.
MacDonald KN; Hall MG; Ivison S; Gandhi S; Klein Geltink RI; Piret JM; Levings MK
Cytotherapy; 2022 Nov; 24(11):1121-1135. PubMed ID: 36008207
[TBL] [Abstract][Full Text] [Related]
9. A robust, good manufacturing practice-compliant, clinical-scale procedure to generate regulatory T cells from patients with amyotrophic lateral sclerosis for adoptive cell therapy.
Alsuliman A; Appel SH; Beers DR; Basar R; Shaim H; Kaur I; Zulovich J; Yvon E; Muftuoglu M; Imahashi N; Kondo K; Liu E; Shpall EJ; Rezvani K
Cytotherapy; 2016 Oct; 18(10):1312-24. PubMed ID: 27497700
[TBL] [Abstract][Full Text] [Related]
10. Generation of Human Alloantigen-Specific Regulatory T Cells Under Good Manufacturing Practice-Compliant Conditions for Cell Therapy.
Cheraï M; Hamel Y; Baillou C; Touil S; Guillot-Delost M; Charlotte F; Kossir L; Simonin G; Maury S; Cohen JL; Lemoine FM
Cell Transplant; 2015; 24(12):2527-40. PubMed ID: 25198125
[TBL] [Abstract][Full Text] [Related]
11. CD28 costimulation is essential for human T regulatory expansion and function.
Golovina TN; Mikheeva T; Suhoski MM; Aqui NA; Tai VC; Shan X; Liu R; Balcarcel RR; Fisher N; Levine BL; Carroll RG; Warner N; Blazar BR; June CH; Riley JL
J Immunol; 2008 Aug; 181(4):2855-68. PubMed ID: 18684977
[TBL] [Abstract][Full Text] [Related]
12. Clinical grade Treg: GMP isolation, improvement of purity by CD127 Depletion, Treg expansion, and Treg cryopreservation.
Peters JH; Preijers FW; Woestenenk R; Hilbrands LB; Koenen HJ; Joosten I
PLoS One; 2008 Sep; 3(9):e3161. PubMed ID: 18776930
[TBL] [Abstract][Full Text] [Related]
13. A Novel GMP Protocol to Produce High-Quality Treg Cells From the Pediatric Thymic Tissue to Be Employed as Cellular Therapy.
Bernaldo-de-Quirós E; Cózar B; López-Esteban R; Clemente M; Gil-Jaurena JM; Pardo C; Pita A; Pérez-Caballero R; Camino M; Gil N; Fernández-Santos ME; Suarez S; Pion M; Martínez-Bonet M; Correa-Rocha R
Front Immunol; 2022; 13():893576. PubMed ID: 35651624
[TBL] [Abstract][Full Text] [Related]
14. Cross talk between human regulatory T cells and antigen-presenting cells: Lessons for clinical applications.
Wardell CM; MacDonald KN; Levings MK; Cook L
Eur J Immunol; 2021 Jan; 51(1):27-38. PubMed ID: 33301176
[TBL] [Abstract][Full Text] [Related]
15. Cell banking for regulatory T cell-based therapy: strategies to overcome the impact of cryopreservation on the Treg viability and phenotype.
Gołąb K; Grose R; Placencia V; Wickrema A; Solomina J; Tibudan M; Konsur E; Ciepły K; Marek-Trzonkowska N; Trzonkowski P; Millis JM; Fung J; Witkowski P
Oncotarget; 2018 Feb; 9(11):9728-9740. PubMed ID: 29515766
[TBL] [Abstract][Full Text] [Related]
16. Cryopreservation of human vascular umbilical cord cells under good manufacturing practice conditions for future cell banks.
Polchow B; Kebbel K; Schmiedeknecht G; Reichardt A; Henrich W; Hetzer R; Lueders C
J Transl Med; 2012 May; 10():98. PubMed ID: 22591741
[TBL] [Abstract][Full Text] [Related]
17. Large-Scale Generation of Human Allospecific Induced Tregs With Functional Stability for Use in Immunotherapy in Transplantation.
Alvarez-Salazar EK; Cortés-Hernández A; Arteaga-Cruz S; Alberú-Gómez J; Soldevila G
Front Immunol; 2020; 11():375. PubMed ID: 32300340
[TBL] [Abstract][Full Text] [Related]
18. Umbilical cord blood regulatory T-cell expansion and functional effects of tumor necrosis factor receptor family members OX40 and 4-1BB expressed on artificial antigen-presenting cells.
Hippen KL; Harker-Murray P; Porter SB; Merkel SC; Londer A; Taylor DK; Bina M; Panoskaltsis-Mortari A; Rubinstein P; Van Rooijen N; Golovina TN; Suhoski MM; Miller JS; Wagner JE; June CH; Riley JL; Blazar BR
Blood; 2008 Oct; 112(7):2847-57. PubMed ID: 18645038
[TBL] [Abstract][Full Text] [Related]
19. Improved GMP compliant approach to manipulate lipoaspirates, to cryopreserve stromal vascular fraction, and to expand adipose stem cells in xeno-free media.
Agostini F; Rossi FM; Aldinucci D; Battiston M; Lombardi E; Zanolin S; Massarut S; Parodi PC; Da Ponte A; Tessitori G; Pivetta B; Durante C; Mazzucato M
Stem Cell Res Ther; 2018 May; 9(1):130. PubMed ID: 29751821
[TBL] [Abstract][Full Text] [Related]
20. Autologous cryopreserved leukapheresis cellular material for chimeric antigen receptor-T cell manufacture.
Tyagarajan S; Schmitt D; Acker C; Rutjens E
Cytotherapy; 2019 Dec; 21(12):1198-1205. PubMed ID: 31837735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
